cancer-patients / English

add

Results from a new phase 1 trial indicate that immunotherapy could be used to treat the most common form of colorectal cancer, also known as bowel cancer. Consistent responses to immunotherapy have been reported in patients with the most…

Researchers have developed a new nanomedicine therapy that delivers anticancer drugs to lung cancer cells and enhances the immune system's ability to fight cancer. The team showed promising results for the new therapy in cancer cells in…

The Princess of Wales was diagnosed after a major abdominal operation in January.

The Princess of Wales was diagnosed after a major abdominal operation in January.

The Princess of Wales was diagnosed after a major abdominal operation in January.

The story of a leukemia survivor has brought the HC for the Ole Miss Rebels to break down at her kind act. A girl named Jocelyn gave out 10 dollars to a man posing to be in need when Jocelyn helped him out without a second thought. The set…

Developing chemotherapy drugs against breast cancer is costly, slow, and often inefficient, with more than 95% of screened drug candidates failing in patient trials.

The drugs - botensilimab and balstilimab - work by triggering the body's immune system to attack cancer cells. The treatment has been described as "potentially game changing"

Trials of the treatment, using a combination of two drugs, showed tumours had shrunk or remained stable in three out of five patients

After six months, tumours were shown to shrink or remain stable in 61% of the patients

The team said it hopes authorities in the UK will be 'able to move quickly' in approving its use

The team said it hopes authorities in the UK will be 'able to move quickly' in approving its use

The combination of two drugs used to boost immune response could shrink tumours in 60 per cent of patients, according to the new research by Anglia Ruskin University

The report was based on responses from senior managers at 60 specialist cancer centres in England, Wales, Scotland and Northern Ireland

After six months, tumours were shown to shrink or remain stable in 61 per cent of the patients phase one results showed

The reason why targeted treatment for non-small cell lung cancer fails to work for some patients, particularly those who have never smoked, has been discovered.

Although very rare, past reports show some cancer patients may develop secondary cancers following lifesaving CAR T-cell therapy.

A study led by the Institute for Bioengineering of Catalonia (IBEC) has investigated how the mechanical properties of different types of colorectal cancer cells influence the process of metastasis. The study, which used patient-derived…